Spondyloenchondrodysplasia

Heterogeneity in this disorder causes the phenotype and severity of the symptoms caused by the disorder to vary widely among patients with the condition, these subsets of symptoms include those affecting the immune system (causing autoimmune diseases and resulting in the disruption of other systems such as the hematological one), the neurological system, and many more. Skeletal symptoms This condition primarily constitutes skeletal anomalies. These include metaphyseal dysplasia, platyspondyly and the presence of lesions located in the long bones and the spinal vertebrae, and enchondroma. Cartilage symptoms This subset of symptoms affecting the cartilage. They include the presence of enchondroma and the failure of cartilage to turn into bone in some parts of the body. Immune symptoms This subset of symptoms primarily affects the immune system (immunodeficiency) and also causes autoimmune diseases, which indirectly affect other systems of the body. These include thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, recurrent respiratory infections and fevers, hemolytic anemia, and hypothyroidism. Neurological symptoms This subset of symptoms affects the central nervous system. These include ataxia, muscle spasticity, intellectual disabilities, and cerebral calcification. Other findings Other features that may be found in patients with this condition include short stature, dental eruption delay, dental malocclusion, vitiligo, seizures, pectus carinatum, kyphosis, kyphoscoliosis, ventriculomegaly, vasculitis, Raynaud's phenomenon, pain affecting the lower limbs, chronic headaches, chronic kidney disease, cranio-facial dysmorphisms, hypoplasia of the iliac bones, lupus nephritis, arthralgia, arthritis, hypocomplementemia, low to absent TRAP enzyme in serum, high levels of interferon-alpha in the serum, and an over-expression of interferon-stimulated genes. Rare symptoms include intellectual disability, developmental delay, progressive spastic quadriplegia, temporomandibular joint pain, hepatosplenomegaly, and spina bifida. Complications Premature death may result from the immunodeficiency and/or autoimmunity associated with this condition. == Genetics ==

This condition is caused by autosomal recessive loss-of-function mutations in the ACP5 gene, located in chromosome 19. This gene encodes an iron-containing enzyme known as tartrate-resistant acid phosphatase, which regulates a protein known as osteopontin. Immune system cells is among the many systems this protein plays a role in. Individuals with this condition have over-active osteopontin protein due to the fact that the TRAP enzyme is unable of inactivating it. The impaired TRAP enzyme is a result of the ACP5 mutation involved with the condition. Osteopontin hyperactivity in patients with spondyloenchondroplasia results in over-produced interferon 1 protein, a bone breakdown process that is longer than usual and an unusually over-active immune system. Both of these altered mechanisms cause skeletal anomalies, autoimmunity, and immunodeficiency as a result. In rare cases, spondyloenchondroplasia may be inherited in an autosomal dominant manner. == Diagnosis ==

There are various ways of diagnosing spondyloenchondroplasia: Physical examination Description of physical findings in patients with spondyloenchondroplasia is essential for a proper diagnosis. The most common physical finding is short stature. The four patients described by Frydman et al. (1986) had a stature that was three standard deviations below average. The two Turkish siblings with the condition reported by De Bruin et al. (2016) had extreme short stature. Radiographs All cases in the medical literature of spondyloenchondroplasia have included a description of the adiological anomalies shown by patients with the condition which were found on radiographs. A 5-year-old Indian boy reported by Kulkarni et al. (2007) had anomalies of his metaphyses and vertebrae bones which were visible under X-ray. These are common skeletal features shared by patients with spondyloenchondroplasia. Two brothers born of a consanguineous first-cousin Iraqi Jewish union had enchondromatosis which was visible under radiographs. One of the four patients analyzed by Menger et al. (1989) had vertebral anomalies that were visible on radiographs. Said patient was the product of father-daughter incest. Uhlmann et al. (1998) found spinal anomalies, flattened bones, and tubular enchondromas in 2 boys with the condition which were visible on radiographs. Genetic testing Genetic testing methods are essential for a diagnosis of spondyloenchondroplasia, said diagnostic methods must detect a mutation in the ACP5 gene of the patient with the condition. Girschick et al. (2015) found a missense mutation and a 1 base pair duplication in the ACP5 gene of a 9-year-old girl with the condition. Both mutations were homozygous. Her parents were heterozygous for only one of the mutations. Genetic testing done on the 5-year-old Indian boy reported by Kulkarni et al. (2007) showed a 5-kb deletion in his ACP5 gene, present in a homozygous state. Sema et al. (2021) found a homozygous mutation (c.155A > C) in the ACP5 gene of a 19-year-old Turkish man with the condition. Among the many patients in the study, Briggs et al. (2011) found a homozygous C>T substitution in exon 4 of the ACP5 gene of two Turkish siblings of the opposite sex which lead to a threonine to isoleucine substitution at amino acid position 89 of the gene. The mutation was found thanks to genetic sequencing. • Metachondromatosis, a rare autosomal dominant genetic disorder characterized by metaphyseal enchondromas and exostoses of the hands and feet. • Genochondromatosis, a very rare autosomal dominant genetic disorder characterized by humeral and femural enchondromas which don't cause short stature. == Treatment ==

Although no standard management strategy for spondyloenchondroplasia exists, there have been various treatment methods done on patients with the condition reported in the medical literature. Growth hormone therapy The 21-year-old sister of the proband reported by Tuyzus et al. (2004) had undergone growth hormone therapy 12 years prior to the study in order to treat her severely short stature. Takanori et al. (2017) described successful treatment for spondyloenchondroplasia-associated short stature with growth hormone therapy on a child with the condition. == Prevalence ==

According to OMIM, only around 30–40 cases have been described in the medical literature. == History ==

Discovery of the disorder This condition was first described in 2003 by Roifman et al., the amount of patients they described was four. The first two patients were a pair of siblings of the opposite sex (brother and sister) born to consanguineous first-cousin Portuguese parents. The sister was noted to have suffered from various health complications, including recurrent infections (primarily those affecting the respiratory system), chronic restrictive lung disease, idiopathic thrombocytopenic purpura, and an enlarged thyroid accompanied by hypothyroidism. Her thrombocytopenic purpura didn't resolve with the use of either prednisone or intravenous immunoglobulin, but it did after a splenectomy was performed on her. The younger brother had presumably died, and had suffered from various ailments like her sister, including recurrent respiratory infections, campylobacter enteritis, idiopathic thrombocytopenic purpura, and encephalitis, the latter of which caused his aforementioned death. == See also ==